Skip to main content
Premium Trial:

Request an Annual Quote

CODA Genomics, Viventia Expand Protein-Expression Collaboration

NEW YORK (GenomeWeb News) — Protein translation company CODA Genomics today said it has expanded an ongoing collaboration with the Canadian antibody developer Viventia Biotech.
 
Under the terms of the agreement, CODA will apply its protein translational engineering systems to “various antibody projects within Viventia,” CODA said.  
 
The Laguna Hills, Calif.-based company said its translational engineering platforms enable synthetic biology advances by “solving problems related to protein expression, activity and solubility.”
 
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.